BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/6/2019 8:31:40 AM | Browse: 888 | Download: 1149
 |
Received |
|
2019-01-29 02:39 |
|
Peer-Review Started |
|
2019-01-29 04:32 |
|
To Make the First Decision |
|
2019-03-27 05:44 |
|
Return for Revision |
|
2019-03-27 07:24 |
|
Revised |
|
2019-03-28 12:32 |
|
Second Decision |
|
2019-04-19 07:10 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-04-20 02:04 |
|
Articles in Press |
|
2019-04-20 02:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-29 02:18 |
|
Publish the Manuscript Online |
|
2019-06-06 08:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Michiel Dirk Voskuil, Amber Bangma, Rinse Karel Weersma and Eleonora Anna Margaretha Festen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michiel Dirk Voskuil, MD, Research Fellow, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, PO Box 30001, Hanzeplein 1, Groningen 9713 GZ, Netherlands. m.d.voskuil@umcg.nl |
| Key Words |
Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Pharmacogenetics; Personalized medicine |
| Core Tip |
In recent years, strong pharmacogenetic associations for drugs used in the management of inflammatory bowel disease (IBD) have been identified. However, the implementation of pre-treatment pharmacogenetic testing into clinical guidelines has been challenging. Particular groups of patients are needlessly exposed to (expensive) drugs that are either ineffective or harmful. Pre-treatment screening for TPMT and NUDT15 genetic variation should be incorporated into clinical IBD management guidelines. Therapeutic recommendations based on HLA genetic variants, conferring risk for thiopurine-induced pancreatitis and immunogenicity to tumor necrosis factor-antagonists, respectively, should be further evaluated. |
| Publish Date |
2019-06-06 08:31 |
| Citation |
Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i21/2539.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i21.2539 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
